David MD - PaxMedica, Common Chief Officer
| PXMDDelisted Stock | USD 0.86 0.18 17.31% |
Executive
David MD is Chief Officer of PaxMedica, Common Stock
| Age | 67 |
| Phone | 914 987 2876 |
| Web | https://www.paxmedica.com |
PaxMedica, Common Management Efficiency
The company has return on total asset (ROA) of (2.5596) % which means that it has lost $2.5596 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (10.4696) %, meaning that it created substantial loss on money invested by shareholders. PaxMedica, Common's management efficiency ratios could be used to measure how well PaxMedica, Common manages its routine affairs as well as how well it operates its assets and liabilities.PaxMedica, Common Stock currently holds 173.54 K in liabilities with Debt to Equity (D/E) ratio of 0.07, which may suggest the company is not taking enough advantage from borrowing. Debt can assist PaxMedica, Common until it has trouble settling it off, either with new capital or with free cash flow. So, PaxMedica, Common's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like PaxMedica, Common Stock sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for PaxMedica, to invest in growth at high rates of return. When we think about PaxMedica, Common's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Joel Yeung | Virax Biolabs Group | N/A | |
| Ryker Willie | Palisade Bio | N/A | |
| Clement Monteil | Virax Biolabs Group | N/A | |
| Lily Fu | Virax Biolabs Group | N/A | |
| Khullani JD | Cardio Diagnostics Holdings | 40 | |
| MD FACC | ZyVersa Therapeutics | 74 | |
| Esq JD | Cardio Diagnostics Holdings | 60 | |
| Pramod Gupta | Unicycive Therapeutics | 64 | |
| Nigel MSc | Virax Biolabs Group | 59 | |
| Joerg Heyer | Palisade Bio | N/A | |
| MD FFPM | Immix Biopharma | 64 | |
| Stefan Sperl | Kiora Pharmaceuticals | N/A | |
| Dmitry MD | Biodexa Pharmaceticals | 44 | |
| Jose MD | Allarity Therapeutics | 67 | |
| Melda Oconnell | ZyVersa Therapeutics | N/A | |
| Gerhard Bauer | Immix Biopharma | N/A | |
| Steve Ellul | Biodexa Pharmaceticals | N/A | |
| Alexander Epshinsky | Allarity Therapeutics | 41 | |
| Melissa CPA | Kiora Pharmaceuticals | 44 | |
| Ben JD | Immix Biopharma | N/A | |
| Mitchell MD | Palisade Bio | 46 | |
Management Performance
| Return On Equity | -10.47 | ||||
| Return On Asset | -2.56 |
PaxMedica, Common Stock Leadership Team
Elected by the shareholders, the PaxMedica, Common's board of directors comprises two types of representatives: PaxMedica, Common inside directors who are chosen from within the company, and outside directors, selected externally and held independent of PaxMedica,. The board's role is to monitor PaxMedica, Common's management team and ensure that shareholders' interests are well served. PaxMedica, Common's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, PaxMedica, Common's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Howard Weisman, CEO Director | ||
| MS MBA, Ex Chairman | ||
| Zachary Rome, COO Director | ||
| Stephen Sheldon, Chief Officer | ||
| David MD, Chief Officer |
PaxMedica, Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is PaxMedica, Common a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -10.47 | ||||
| Return On Asset | -2.56 | ||||
| Current Valuation | 388.33 K | ||||
| Shares Outstanding | 7.47 M | ||||
| Shares Owned By Insiders | 8.14 % | ||||
| Shares Owned By Institutions | 1.60 % | ||||
| Number Of Shares Shorted | 637.72 K | ||||
| Price To Earning | 1.90 X | ||||
| Price To Book | 1.83 X | ||||
| EBITDA | (16.15 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Other Consideration for investing in PaxMedica, Pink Sheet
If you are still planning to invest in PaxMedica, Common Stock check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the PaxMedica, Common's history and understand the potential risks before investing.
| Stocks Directory Find actively traded stocks across global markets | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |